BioRad Introduces AntiVedolizumab Antibodies
Antibodies used to support research into the treatment of ulcerative colitis and Crohn’s disease
View ArticleBioRad Introduces AntiVedolizumab Antibodies Antibodies Used to Support...
HERCULES Calif.–May 15 2018–BioRad Laboratories Inc. NYSE BIO and BIOb a global leader of life science research and clinical diagnostic products today announced the release of a...
View ArticleThe Revolution in Inflammation Drug Development
Chronic autoimmune and inflammatory diseases are painful and often lifelong conditions. I know this both as a scientist and a father as my son Jeremy was diagnosed 12 years ago with Crohns disease one...
View ArticleQueens Medical Associates to Hold Inaugural Clinical Trials Day on May 22
Leading oncology and hematology practice educates public on importance of clinical trials patient opportunities and advances in cancer treatmentNEW YORK PRWEB May 16 2018 In recognition of National...
View ArticleTxCell SA TXCL Pharmaceuticals Healthcare Deals and Alliances Profile Report...
SummaryTxcell SA Txcell is a biotechnology company that develops and innovates cellbased immunotherapy utilizing antigen specific regulatory Tcells. The company's pipeline products include cartreg...
View ArticlePhase III IMpower150 Study Showed Genentechs TECENTRIQ and Avastin Plus...
A survival advantage for the TECENTRIQ and Avastin combination regimen was observed in all prespecified exploratory patient subgroups analyzed including people with EGFR and ALK mutations liver...
View ArticleBioRad Laboratories antivedolizumab antibodies
Vedolizumab Entyvio is a monoclonal antibody that is used to treat ulcerative colitis inflammatory bowel disease and Crohns disease. BioRads antivedolizumab antibodies which support research into the...
View ArticleEsperite NV ESP with The Cell Factory has signed the agreement with the PHARM...
AmsterdamÂThe NetherlandsÂ17th May 2018 Esperite's The Cell Factory has signed today the agreement with PHARM the Italian CRO company which is preparing for the firstinman clinical trials...
View ArticleFrank Russomano Elected to National Board of Trustees of Crohns & Colitis...
President and CEO of US HealthConnect Inc. leverages 25 years of experience in healthcare education and personal family experience with Crohns Disease to help the Foundation meet its missionFORT...
View ArticleFilgotinib may improve health and quality of life in people with rheumatoid...
Filgotinib on its own or in combination with methotrexate appears to increase quality of life measures in people with rheumatoid arthritis and reduces some symptoms says new research in Arthritis...
View ArticleSetPoint Medical Appoints Ankit Shah to Lead Commercialization and Marketing
Commercialization Expertise Beneficial as SetPoint Advances its Clinical Program SetPoint Medical a clinicalstage biomedical technology company developing bioelectronic therapy for chronic inflammatory...
View ArticleSublimity Therapeutics Closes US$64 Million Financing to Fund Development of...
Orally delivered soluble formulation of cyclosporine represents promising new treatment option for patients with moderate to severe ulcerative colitis DUBLIN Ireland May 22 2018 GLOBE NEWSWIRE...
View ArticleLandos Biopharma to Participate in Upcoming Digestive Disease Week Conference...
Landos Biopharma an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases announced that the company would be participating in
View ArticleCalypso Biotech SA Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryCalypso Biotech SA Calypso is a biopharmaceutical company that develops antibody therapies. The company's pipeline products include CALY0001 and CALY0002. Its CALY0001 therapeutic antibody is...
View ArticleSandoz receives European Commission approval for Zessly infliximab in...
Novartis International AG Sandoz receives European Commission approval for Zessly infliximab in gastroenterological rheumatological and dermatological diseases . Processed and transmitted by Nasdaq...
View ArticleNovartis' Sandoz scores EU approval for Remicade biosimilar
The European Commission has given its approval to Sandoz Novartis generics and biosimilars unit for its biosimilar version of Janssens Remicade infliximab and other products known as Zessly.The therapy...
View ArticleRedHill BioPharma RDHL Continued GI product growth CD PhIII data in 3M
Edison Investment Research Pharmaceutical & healthcare RedHill Biopharma With its Q118 results RedHill reported GI product revenues growing by 22 qoq to $2.4m in Q118. It also provided updates on...
View ArticleCalgary Researchers Discover a Novel Approach to Treatment of Inflammatory...
Antibe Therapeutics Inc. "Antibe" or the Company TSXVATE OTCQBATBPF is pleased to announce that a team of researchers at the University of Calgary has identified a key mechanism underlying the ability...
View ArticleRedHill BioPharma BPCRRDHL Continued GI product growth CD PhIII data in 3M
Edison Investment Research Investment Companies BioPharma Credit Pharmaceutical & healthcare RedHill Biopharma With its Q118 results RedHill reported GI product revenues growing by 22 qoq to $2.4m...
View Article